These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25481761)

  • 41. The rise and spread of a new pathogen: seroresistant Moraxella catarrhalis.
    Wirth T; Morelli G; Kusecek B; van Belkum A; van der Schee C; Meyer A; Achtman M
    Genome Res; 2007 Nov; 17(11):1647-56. PubMed ID: 17895425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of ketolides HMR 3647 [correction of HRM 3647] and HMR 3004 [correction of HRM 3004], levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis.
    Sáez-Nieto JA; Vázquez JA
    Antimicrob Agents Chemother; 1999 Apr; 43(4):983-4. PubMed ID: 10103218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Have we reached the point of no return? The hidden impact of antibacterial resistance in respiratory tract infection. Introduction.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S2-4; discussion S26-7. PubMed ID: 11419670
    [No Abstract]   [Full Text] [Related]  

  • 44. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections.
    Shaikh SB; Ahmed Z; Arsalan SA; Shafiq S
    Infect Drug Resist; 2015; 8():263-7. PubMed ID: 26261422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In vitro comparative activity of five macrolides against 190 Branhamella catarrhalis strains].
    Chardon H; Bellon O; Bourgeois F; Lagier E
    Pathol Biol (Paris); 1989 May; 37(5):382-5. PubMed ID: 2506512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Sato K
    J Infect Chemother; 2000 Sep; 6(3):188. PubMed ID: 11810563
    [No Abstract]   [Full Text] [Related]  

  • 47. Mutation of TonB-Dependent Receptor Encoding Gene
    Zhang Z; Yang Z; Xiang X; Liao P; Niu C
    Infect Drug Resist; 2022; 15():2419-2426. PubMed ID: 35547787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic susceptibility of Neochlamydia hartmanellae and Parachlamydia acanthamoebae in amoebae.
    Vouga M; Diabi H; Boulos A; Baud D; Raoult D; Greub G
    Microbes Infect; 2015; 17(11-12):761-5. PubMed ID: 26279002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity.
    Maračić S; Kraljević TG; Paljetak HČ; Perić M; Matijašić M; Verbanac D; Cetina M; Raić-Malić S
    Bioorg Med Chem; 2015 Dec; 23(23):7448-63. PubMed ID: 26578325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of
    Liu YL; Ding R; Jia XM; Huang JJ; Yu S; Chan HT; Li W; Mao LL; Zhang L; Zhang XY; Wu W; Ni AP; Xu YC
    Emerg Microbes Infect; 2022 Dec; 11(1):2055-2068. PubMed ID: 35904140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biophysical and in silico interaction studies of aporphine alkaloids with Malonyl-CoA: ACP transacylase (FabD) from drug resistant Moraxella catarrhalis.
    Kumar V; Sharma A; Pratap S; Kumar P
    Biochimie; 2018 Jun; 149():18-33. PubMed ID: 29604333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An integrated complete-genome sequencing and systems biology approach to predict antimicrobial resistance genes in the virulent bacterial strains of Moraxella catarrhalis.
    Bristy SA; Hossain MA; Hasan MI; Mahmud SMH; Moni MA; Rahman MH
    Brief Funct Genomics; 2023 Jul; 22(4):375-391. PubMed ID: 36881677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel mechanism responsible for high-level macrolide resistance in
    Kasai A; Ohta A; Maeda Y; Yamada K; Tao K; Saito R
    Infect Drug Resist; 2018; 11():2137-2140. PubMed ID: 30464556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simkania negevensis, an Example of the Diversity of the Antimicrobial Susceptibility Pattern among Chlamydiales.
    Vouga M; Baud D; Greub G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis.
    Olivieri I; Padula A; Armignacco L; Sabatella V; Mancino M
    Ann Rheum Dis; 2004 Jan; 63(1):105-6. PubMed ID: 14672904
    [No Abstract]   [Full Text] [Related]  

  • 56. Tribolium castaneum defensin 1 kills Moraxella catarrhalisin an in vitro infection model but does not harm commensal bacteria.
    Bertrams W; Lindhauer NS; Rieke MC; Paas A; Hoffmann K; Greene B; Visekruna A; Vilcinskas A; Seidel K; Schmeck B
    Virulence; 2021 Dec; 12(1):1003-1010. PubMed ID: 33843461
    [No Abstract]   [Full Text] [Related]  

  • 57. RECIPROCAL GENETIC TRANSFORMATION BETWEEN NEISSERIA CATARRHALIS AND MORAXELLA NONLIQUEFACIENS.
    CATLIN BW
    J Gen Microbiol; 1964 Dec; 37():369-79. PubMed ID: 14250800
    [No Abstract]   [Full Text] [Related]  

  • 58. Diffusion of macrolide antibiotics through the outer membrane of Moraxella catarrhalis.
    Tsujimoto H; Gotoh N; Nishino T
    J Infect Chemother; 1999 Dec; 5(4):196-200. PubMed ID: 11810516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low prevalence of Moraxella catarrhalis in the patients who suffered from conjunctivitis in the southwest of Iran.
    Farajzadeh Sheikh A; Feghhi M; Torabipour M; Saki M; Veisi H
    BMC Res Notes; 2020 Nov; 13(1):547. PubMed ID: 33239090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moraxella osloensis, an emerging pathogen of endocarditis in immunocompromised patients?
    Gagnard JC; Hidri N; Grillon A; Jesel L; Denes E
    Swiss Med Wkly; 2015; 145():w14185. PubMed ID: 26376092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.